These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38079232)

  • 1. Statistical Methods to Evaluate Surrogate Markers.
    Parast L; Tian L; Cai T; Palaniappan L
    Med Care; 2024 Feb; 62(2):102-108. PubMed ID: 38079232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating surrogate marker information using censored data.
    Parast L; Cai T; Tian L
    Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using a surrogate marker for early testing of a treatment effect.
    Parast L; Cai T; Tian L
    Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers.
    Parast L; Tian L; Cai T; Palaniappan LP
    BMJ Open Diabetes Res Care; 2023 Oct; 11(5):. PubMed ID: 37907279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.
    Zhou RR; Zhao SD; Parast L
    Stat Med; 2022 May; 41(12):2227-2246. PubMed ID: 35189671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
    Parast L; McDermott MM; Tian L
    Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate markers and joint models for longitudinal and survival data.
    Taylor JM; Wang Y
    Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rank-based approach to evaluate a surrogate marker in a small sample setting.
    Parast L; Cai T; Tian L
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38386359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models.
    Huang J; Huang B
    Stat Biopharm Res; 2010 May; 2(2):229-238. PubMed ID: 20577652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogacy marker paradox measures in meta-analytic settings.
    Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
    Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing for heterogeneity in the utility of a surrogate marker.
    Parast L; Cai T; Tian L
    Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis for the evaluation of potential surrogate markers.
    Daniels MJ; Hughes MD
    Stat Med; 1997 Sep; 16(17):1965-82. PubMed ID: 9304767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proportion of treatment effect (PTE) explained by a surrogate marker.
    Chen C; Wang H; Snapinn SM
    Stat Med; 2003 Nov; 22(22):3449-59. PubMed ID: 14601012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust methods to correct for measurement error when evaluating a surrogate marker.
    Parast L; Garcia TP; Prentice RL; Carroll RJ
    Biometrics; 2022 Mar; 78(1):9-23. PubMed ID: 33021738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
    Cowles MK
    Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.